Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sanbio Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split across 2 distinct art units, indicating that the company's biotech and pharmaceutical innovations are being reviewed by different specialized units. This division across 2 art units requires the company to adapt to the examination cultures within each unit.
The portfolio involves 2 distinct examiners, matching the total of 2 pending office actions. DRISCOLL, LORA E BARNHART is the busiest examiner for the company, currently overseeing 1 pending office action. This distribution shows that each pending matter is being handled by a separate examiner, requiring the company to navigate different examiner perspectives. With 2 distinct examiners and 2 distinct art units for the 2 pending actions, the company's prosecution is decentralized. This means that the outcome of 1 pending action is unlikely to be influenced by the progress of the other, as they are handled by different individuals in different units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 84d |
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 84d |
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19293815 | NEURAL REGENERATING CELLS WITH ALTERATIONS IN DNA METHYLATION | DRISCOLL, LORA E BARNHART | 3991 | §101Other | Non-Final OA | — | Pending | Aug 07, 2025 |
| 18605731 | METHODS AND COMPOSITIONS FOR MODULATING DOPAMINERGIC NEURONS | SCHUBERG, LAURA J | 1631 | §103§112 | Final Rejection | 84d | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial